Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been given a consensus rating of “Moderate Buy” by the nine ratings firms that are covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $59.44.

HALO has been the subject of a number of recent research reports. Morgan Stanley upped their target price on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. HC Wainwright reaffirmed a “buy” rating and set a $65.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, August 8th. JPMorgan Chase & Co. lowered their target price on shares of Halozyme Therapeutics from $53.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Wells Fargo & Company raised their price target on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the stock an “overweight” rating in a research note on Friday, June 7th. Finally, The Goldman Sachs Group lifted their price objective on Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a report on Monday, July 22nd.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 10,000 shares of the business’s stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $51.93, for a total value of $519,300.00. Following the transaction, the chief financial officer now owns 15,480 shares of the company’s stock, valued at $803,876.40. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CFO Nicole Labrosse sold 10,000 shares of the company’s stock in a transaction dated Thursday, June 27th. The shares were sold at an average price of $51.93, for a total transaction of $519,300.00. Following the transaction, the chief financial officer now owns 15,480 shares in the company, valued at approximately $803,876.40. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Matthew L. Posard sold 9,881 shares of the stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total transaction of $570,133.70. Following the sale, the director now directly owns 69,874 shares in the company, valued at approximately $4,031,729.80. The disclosure for this sale can be found here. Insiders sold 64,881 shares of company stock valued at $3,585,084 in the last three months. Corporate insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. TD Asset Management Inc raised its position in shares of Halozyme Therapeutics by 517.0% during the fourth quarter. TD Asset Management Inc now owns 1,983,916 shares of the biopharmaceutical company’s stock worth $73,326,000 after acquiring an additional 1,662,390 shares during the last quarter. Norges Bank bought a new stake in Halozyme Therapeutics during the 4th quarter worth about $44,935,000. Epoch Investment Partners Inc. lifted its position in Halozyme Therapeutics by 250.5% during the 4th quarter. Epoch Investment Partners Inc. now owns 1,163,033 shares of the biopharmaceutical company’s stock valued at $42,986,000 after purchasing an additional 831,199 shares during the period. Boston Partners boosted its stake in shares of Halozyme Therapeutics by 562.2% in the 4th quarter. Boston Partners now owns 552,392 shares of the biopharmaceutical company’s stock valued at $20,218,000 after purchasing an additional 468,977 shares during the last quarter. Finally, LSV Asset Management bought a new stake in shares of Halozyme Therapeutics during the fourth quarter worth approximately $17,090,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Down 0.9 %

Halozyme Therapeutics stock opened at $61.64 on Friday. Halozyme Therapeutics has a one year low of $32.83 and a one year high of $62.58. The company’s fifty day moving average price is $54.23 and its two-hundred day moving average price is $45.60. The company has a debt-to-equity ratio of 8.44, a current ratio of 6.64 and a quick ratio of 5.36. The company has a market capitalization of $7.85 billion, a price-to-earnings ratio of 25.47, a PEG ratio of 0.56 and a beta of 1.27.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.18. The business had revenue of $231.40 million for the quarter, compared to analyst estimates of $204.94 million. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.68 EPS. On average, analysts forecast that Halozyme Therapeutics will post 3.66 earnings per share for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.